Xvivo Perfusion AB ( (XVIPF) ) has released its Q1 earnings. Here is a breakdown of the information Xvivo Perfusion AB presented to its investors.
Xvivo Perfusion AB is a medical technology company specializing in organ preservation and transplantation solutions, operating primarily in the healthcare sector with a focus on thoracic and abdominal organ systems.
In its latest earnings report for the first quarter of 2025, Xvivo Perfusion AB highlighted significant regulatory achievements and a notable increase in net sales across its thoracic and abdominal segments.
The company reported total net sales of SEK 218.6 million, an 18% increase compared to the same period last year. The thoracic segment saw net sales rise to SEK 141.7 million, while the abdominal segment increased to SEK 56.6 million. Despite these gains, the company faced challenges with a net loss of SEK 12.4 million, attributed to financial expenses and exchange rate differences.
Operating income improved to SEK 26.6 million, with an adjusted EBIT margin of 14%. The gross margin remained steady at 73%, reflecting efficient cost management. The company also reported an adjusted EBITDA of SEK 46.2 million, indicating a solid operational performance.
Looking forward, Xvivo Perfusion AB remains focused on expanding its market presence and advancing its clinical trials, aiming to enhance its financial performance and achieve long-term growth in the organ transplantation sector.